Posts Tagged ‘Clinical’

Provectus Pharmaceuticals Completes Patient Accrual in Phase 2C Clinical Trial of PH-10 for Psoriasis

Provectus Pharmaceuticals Completes Patient Accrual in Phase 2C Clinical Trial of PH-10 for Psoriasis
KNOXVILLE, Tenn.–(BUSINESS WIRE)–Provectus Pharmaceuticals has completed patient accrual in its Phase 2C clinical trial of PH-10 for psoriasis.

Read more on Business Wire

Enzon to discontinue PEG-SN38 clinical program in metastatic colorectal cancer

Enzon to discontinue PEG-SN38 clinical program in metastatic colorectal cancer
Enzon Pharmaceuticals, Inc. today announced that, in light of evolving standards of care for the treatment of metastatic colorectal cancer (mCRC), the Company will discontinue its PEG-SN38 (EZN-2208) clinical program in this disease, following conclusion of its Phase II study.

Read more on News-Medical-Net

AACR 2010: Adaptive design for clinical trials

Dr Donald Berry, of the MD Anderson Cancer Center, University of Texas, talks about adaptive deisgn for clinical trials. This includes identifying which patient populations benefit most, indentifying which drugs are most effective and the doses to be used in future trials. He also discusses the drugs investigated for target therapies, specifically for breast cancer treatment. Speaking from the 2010 AACR conference.

CytRx Begins Phase 1b Clinical Trial with INNO-206 in Patients with Advanced Solid Tumors

CytRx Begins Phase 1b Clinical Trial with INNO-206 in Patients with Advanced Solid Tumors
CytRx Corporation , a biopharmaceutical company specializing in oncology, today announced that it has initiated an open-label Phase 1b safety and dose escalation clinical trial with INNO-206 at the Sarcoma Oncology Center in Santa Monica, California.

Read more on Business Wire via Yahoo! Finance

The Valley Hospital and Webmedx Partner to Reduce DNFB, Improve Clinical Documentation and Automate Quality Reporting

The Valley Hospital and Webmedx Partner to Reduce DNFB, Improve Clinical Documentation and Automate Quality Reporting
Webmedx, a leading medical content provider and the third largest medical transcription service in the U.S., today announced that The Valley Hospital, a 451-bed acute care facility and member of Valley Health System in Ridgewood, New Jersey, has begun an enterprise-wide implementation of Webmedx’s newest solution for clinical documentation improvement and quality reporting, QualityAnalyticsâ¢.

Read more on PR Newswire via Yahoo! Finance

New Study in Clinical Cancer Research Demonstrates Potential for Cyclacel’s Seliciclib in Treating Breast Cancer …

New Study in Clinical Cancer Research Demonstrates Potential for Cyclacel’s Seliciclib in Treating Breast Cancer …
BERKELEY HEIGHTS, N.J. — Cyclacel Pharmaceuticals, Inc. today announced that a newly published study demonstrates that the company’s seliciclib , an orally available inhibitor of multiple cyclin-dependent kinases , reversed resistance to the aromatase inhibitor letrozole and killed hormone receptor positive breast cancer cells that had become insensitive to the effects of letrozole.  The new …

Read more on GlobeNewswire via Yahoo! Finance

Immunovaccine Announces Preliminary Safety Results from Phase I Clinical Trial of DPX-0907 Cancer Vaccine

Immunovaccine Announces Preliminary Safety Results from Phase I Clinical Trial of DPX-0907 Cancer Vaccine
HALIFAX, NOVA SCOTIA–(Marketwire – Dec. 14, 2010) – Immunovaccine Inc. (TSX VENTURE:IMV) today announced preliminary safety results for its Phase I clinical trial of DPX-0907, a DepoVaxT-based therapeutic cancer vaccine candidate for the treatment of patients with advanced stage breast, ovarian or prostate cancer. In this trial, patients receive three subcutaneous injections of either 0.25 mL …

Read more on Marketwire

BioAlliance presents AMEP preclinical, phase I clinical results for melanoma at Electrochemotherapy Meeting

BioAlliance presents AMEP preclinical, phase I clinical results for melanoma at Electrochemotherapy Meeting
BioAlliance Pharma SA, a company dedicated to the supportive care and treatment of cancer patients, presented preclinical and promising preliminary phase I clinical results with its AMEP biotherapy at the “Electrochemotherapy 1st International Users’ Meeting”(Bologna, Italy, November 19-20, 2010).

Read more on News-Medical-Net

Cylene To Present Advances With Industry’s Only Clinical CK2 Inhibitor, CX-4945, At EORTC-NCI-AACR

Cylene To Present Advances With Industry’s Only Clinical CK2 Inhibitor, CX-4945, At EORTC-NCI-AACR
Cylene Pharmaceuticals, Inc. will present advances in the development of their first-in-class, CK2 inhibitor CX-4945, at the 22nd EORTC-NCI-AACR symposium on Molecular Targets and Cancer Therapeutics, to be held on November 16-19 in Berlin, Germany. CX-4945 is the first and only CK2 inhibitor to have entered clinical trials and represents an exciting new approach for the treatment for many …

Read more on Medical News Today

S*BIO’s SB1317 enters Phase 1 clinical trial in patients with advanced/refractory hematologic malignancies

S*BIO’s SB1317 enters Phase 1 clinical trial in patients with advanced/refractory hematologic malignancies
S*BIO Pte Ltd today announced that a fourth novel, potential best-in-class compound discovered and developed by S*BIO has entered a Phase 1 clinical trial. The initiation of the study for S*BIO’s oral multi-kinase inhibitor, SB1317 or TG02, in patients with advanced/refractory hematologic malignancies has triggered a payment from S*BIO’s development and commercialization partner for the program …

Read more on News-Medical-Net